A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Apixaban (Eliquis)
DRUG: Dabigatran etexilate (Pradaxa)
DRUG: Warfarin (Marevan)

TERMINATED

Status

70000

Enrollment

INDUSTRY

Sponsor class

Stopped After feasibility assessment and due to delays in data receipt study was terminated

Conditions

Bayer